



073406.0403 (Formerly 248/037)  
Patent

#10  
yc  
5-3101

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Pelletier, et al.

Title: DEVELOPMENT OF NOVEL  
ANTIMICROBIAL AGENTS  
BASED ON BACTERIOPHAGE  
GENOMICS

Appl. No.: 09/454,252

Filing Date: 12/02/1999

Examiner: Tu, S.

Art Unit: 1653

|  |                   |
|--|-------------------|
| <b>CERTIFICATE OF MAILING</b>  |                   |
| I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below. |                   |
| <u>Karin E. Harden</u>   | (Printed Name)    |
| <u>Karin E. Harden</u>   | (Signature)       |
| <u>May 14, 2001</u>  | (Date of Deposit) |

**RECEIVED**  
MAY 24 2001  
TECH CENTER 1600/2900

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to Office Action mailed March 13, 200, in which the Examiner identified 8 inventions and required the election of claims corresponding to one group, Applicants hereby elect Group I, encompassing claims 9 (in part), 36-37, 61-64 and 93-99, with traverse. Applicants understand that amended claim 9 is regarded as a linking claim generic to the claim groups, and thus is included in part with each group. As required, Applicants further elect *Staphylococcus aureus* and bacteriophage 77 of *Staphylococcus aureus* also with traverse.

As indicated by the Examiner, Applicants understand that if linking claim 9 is found allowable, then the non-elected claim groups would be rejoined for examination in this application.